Cedric Hermans and Mike Makris, current and past editors of Haemophila, the official journal of the WFH, discuss the global importance of the newly published...
Gene therapy for hemophilia: the once elusive promise of gene therapy may become a reality in the very near future. After decades of clinical work,...
Update to WFH Notice: recall of desmopressin nasal spray by Ferring Pharmaceuticals (July 20, 2020) August 4, 2020 In mid-July, Ferring Pharmaceuticals initiated a voluntary precautionary...
This 3rd edition of the World Federation of Hemophilia (WFH) Guidelines for the Management of Hemophilia offers up-to-date guidance and practical recommendations on the diagnosis and management...
The Lancet Haematology has published an editorial praising the work the World Federation of Hemophilia (WFH) is doing for the global bleeding disorders community. The...
Date, time: Thursday, July 30 at 10:00 am EDT (14:00 UTC/GMT) Zoom link: https://us02web.zoom.us/webinar/register/WN_xCGkRetmTfyVXYui5U8Xkg On Thursday, July 30 at 10:00 a.m. EDT (14:00 UTC/GMT), the...
The COVID-19 pandemic has created massive challenges for the bleeding disorders community—especially when it comes to ensuring uninterrupted care for people with hemophilia (PWH). Nepal...
July 20, 2020 The WFH has learned of a voluntary product recall of desmopressin nasal spray by Ferring Pharmaceuticals, due to out of specification results...
The following is the second in a 3-part series about how NMOs in the Middle East region have responded to the coronavirus disease 2019 (COVID-19)...
On June 23, the WFH Humanitarian Aid Program held a webinar called “Virtual Case Conference and Bedside Rounds” to give participants the chance to share...
Since the World Federation of Hemophilia (WFH) launched the Global VWD Call to Action in 2018, the visibility and awareness of von Willebrand Disease (VWD)...
Sanofi and Sobi, have announced an extension of their support of the WFH Humanitarian Aid Program with an additional donation of up to 500 million...